• Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
2
Jul
2015

Q&A With Shire CEO Flemming Ornskov on Becoming More ‘Biotech-Like’

/
Luke Timmerman
/
0
/
All, People
02 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Jun
2015

LinkedIn Is Integral to Biotech, But Some Still Don’t Get It

/
Luke Timmerman
/
3
/
All, People, The Edge
29 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Jun
2015

The Cubist Alumni: Where Are They Now?

/
Luke Timmerman
/
2
/
All, People
25 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jun
2015

The Long Slog For Better Drug Safety Monitoring Is Paying Off

/
Luke Timmerman
/
0
/
All, FDA, The Edge
22 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2015

Like the TR? Tell a Friend to Subscribe, and Enter to Win a T-Shirt

/
Luke Timmerman
/
0
/
All
19 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2015

Who’s Exploring DNA ‘Dark Matter’ for Drug Discovery?

/
Luke Timmerman
/
0
/
All, Genomics
19 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Jun
2015

It’s Time to Re-Think Some Assumptions About Cancer R&D

/
Luke Timmerman
/
4
/
All, Cancer, Drugs, The Edge
15 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Jun
2015

NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
11 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Jun
2015

Bristol-Myers Should Drop the Bully Act. Non-Competes Are Bad for Biotech

/
Luke Timmerman
/
2
/
All, People, The Edge
08 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jun
2015

Cancer is Hot, Diabetes is Not: Watch for Drug Safety and Cost Debates at ADA

/
Luke Timmerman
/
5
/
All, Drugs
05 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Jun
2015

Big Pharma Talent Is Flocking to Biotech Startups. Nobody’s Saying ‘Are You Nuts?’

/
Luke Timmerman
/
2
/
All, People, The Edge
01 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
May
2015

Cancer Immunotherapy’s Amazing Four-Year Run: A Timeline of Events

/
Luke Timmerman
/
4
/
All, Cancer, Drugs
29 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
May
2015

Long-Term Relationships May Not Count in Many Businesses, But They Do in Biotech

/
Luke Timmerman
/
2
/
All, People, The Edge
26 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
May
2015

The Genentech Alumni: Where Are They Now?

/
Luke Timmerman
/
3
/
All, Cancer, People
22 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
May
2015

Why a Pfizer R&D Exec Joined Synlogic to Make ‘Therapeutic Synthetic Life’

/
Luke Timmerman
/
3
/
All, Drugs
21 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
May
2015

Zigging Away From the Herd: Lilly’s Road-Less-Traveled R&D Strategy

/
Luke Timmerman
/
0
/
All, Drugs, The Edge
18 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
May
2015

More than Moderna: Who’s Who in mRNA Therapeutics?

/
Luke Timmerman
/
2
/
All, Drugs, Science
15 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
May
2015

Baseball, Regression to the Mean, and Avoiding Potential Clinical Trial Biases

/
Kyle Serikawa
/
0
/
All, Genomics, Strategy
14 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
May
2015

How Do VCs Divvy Up Their Pay?

/
Luke Timmerman
/
1
/
All, The Edge, Venture Capital
11 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
May
2015

Gates Foundation VC Portfolio: Where is the Global Health Investment Going?

/
Luke Timmerman
/
6
/
All, Diagnostics, Strategy
07 May 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 79 80 81 82 83 84 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2026, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder